Radar · Immunotherapy in South Korea
Best Immunotherapy Companies in South Korea
The 81 best Immunotherapy companies in South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cellid.
By Rohit KhannaTrends & Stories
81companies tracked
$3.3Bdisclosed funding
0unicorns
32have raised
Sources & further reading
- ResearchAndMarkets.com
- The Business Research Company
FLIAR INTELLIGENCE · IMMUNOTHERAPY × SOUTH KOREA
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
69%cloud-native stacks
2025funding peak (by rounds)
2017median founding year
42median Fliar Index™
Ranked: Best Immunotherapy companies in South Korea
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cellid Developer of personalized vaccines to treat cancer and infectious diseases 32Patents top 32%Funding top 35%Innovation top 40%Moat top 45% All 8 signals ▾Patentstop 32% Fundingtop 35% Innovationtop 40% Moattop 45% Marketbottom 48% Globalbottom 35% Fin. healthbottom 35% Techbottom 22% Patents: 32 patents matched (strict assignee match) · 26 filings since 2022 vs 4 in 2017-21 Funding: Raised $2.4B across 1 rounds · 1 rounds over 12 yrs (0.1/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $2.4B | 120 mo ago | 68 | — | PHPNginxNaver Analytics+5 | Public | 32 patents NK cell-based cancer vaccines and replication-deficient adenoviral vector platforms | — |
| 2 | Genexine Developer of immunotherapeutics for treating orphan diseases, cancers & autoimmune disorders 40Product top 14%Patents top 25%Innovation top 32%Funding top 38% All 11 signals ▾Producttop 14% Patentstop 25% Innovationtop 32% Fundingtop 38% Talenttop 38% Moattop 41% Growthtop 45% Globalbottom 45% Marketbottom 37% Fin. healthbottom 34% Techbottom 23% Product: 10 distinct product lines · Company stage: Public Patents: 357 patents matched (strict assignee match) · 113 filings since 2022 vs 151 in 2017-21 rank vs industry peers · Fliar Intelligence Index 40/100 | $233M | 99 mo ago | — | Young Sung Founder & Chairman | NginxGoogle Font APIUnpkg+6 | Public | 355 patents Cytokine‑fusion proteins and single‑domain antibodies for cancer immunotherapy | — |
| 3 | Orum Therapeutics Developer of cell-penetrating antibodies as oncology therapeutics 55Funding top 19%Patents top 23%Moat top 26%Innovation top 35% All 10 signals ▾Fundingtop 19% Patentstop 23% Moattop 26% Innovationtop 35% Talenttop 41% Growthtop 47% Globalbottom 47% Marketbottom 44% Techbottom 42% Newsbottom 41% Funding: Raised $92.0M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) Patents: 121 patents matched (strict assignee match) · 66 filings since 2022 vs 53 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $92M | 6 mo ago | 38 | Sj Lee CEO | Cart FunctionalitySquarespace CommerceSquarespace+14 | Public | 121 patents Targeted antibody‑drug conjugates, neodegrader molecules, and T‑cell activation therapeutics | — |
| 4 | ABL Bio Bi-specific antibodies and Antibody-drug Conjugate immunotherapies for oncology and neurodegenerative diseases | $65M | 96 mo ago | 93 | Sang Hoon Lee Ceo/Founder | BootstrapApache HTTP ServerSwiper+5 | Public | 273 patents Bispecific therapeutic antibodies targeting tumor antigens and immune co‑stimulatory receptors | — |
| 5 | ImmuneOncia Developer of monoclonal and specific antibody for cancer treatment 11Funding top 37%Moat top 39%Market bottom 32%Global bottom 32% All 5 signals ▾Fundingtop 37% Moattop 39% Marketbottom 32% Globalbottom 32% Techbottom 23% Funding: Raised $60.5M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 11/100 | $60M | 53 mo ago | 21 | — | PHPGSAPApache HTTP Server+7 | Public | — | — |
| 6 | Wellmarker Bio Developer of biomarker-based therapeutics for the treatment of cancer | $45M | 83 mo ago | 58 | Dong Hoon Co-Founder & Co-CEO | — | Series B | 85 patents Targeted antibody therapeutics and biomarkers for cancer and kinase inhibitor response | — |
| 7 | Aston Sci. Developer of therapeutic solutions for the treatment of cancer, CNS diseases, and geriatric diseases | $40M | 54 mo ago | 24 | — | — | Series C | — | — |
| 8 | IMBiologics Developer of antibody therapeutics to treat cancer and autoimmune diseases 40Moat top 32%Funding top 33%Patents top 36%Innovation top 45% All 6 signals ▾Moattop 32% Fundingtop 33% Patentstop 36% Innovationtop 45% Marketbottom 41% Globalbottom 40% Moat: Editorial + unicorn rating 4/10 · IP moat: 23 patents Funding: Raised $33.8M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $34M | 35 mo ago | 25 | — | — | Public | 23 patents Engineered antibody/fusion protein therapeutics with half-life extension and bispecific immune targeting | — |
| 9 | LISCure Developer of bacteria-mediated immunotherapeutic drugs for multiple diseases | $26M | 63 mo ago | 7 | Hwaseop Chin CEO | — | Series B | — | — |
| 10 | Tikaros Developer of immunotherapies for the treatment of cancer | $24M | 57 mo ago | — | Kyungho Choi Co-Founder | Windows ServerYouTubeMicrosoft ASP.NET+12 | Series C | — | — |
| 11 | Must Bio Developer of immunotherapeutics for cancer treatment 27Funding top 29%Talent bottom 49%Market bottom 36%Global bottom 29% All 4 signals ▾Fundingtop 29% Talentbottom 49% Marketbottom 36% Globalbottom 29% Funding: Raised $23.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 27/100 | $24M | 3 mo ago | 18 | Kim Seop CEO | — | Series C | — | — |
| 12 | Progen Developer of immunotherapies for immune diseases and cancer 62Growth top 5%Partners top 18%News top 19%Moat top 25% All 10 signals ▾Growthtop 5% Partnerstop 18% Newstop 19% Moattop 25% Patentstop 39% Innovationtop 48% Fundingbottom 49% Talentbottom 49% Marketbottom 48% Globalbottom 36% Partners: 5 contract events in 12 mo · Named contractor/client in 5 deals rank vs industry peers · Fliar Intelligence Index 62/100 | $23M | 38 mo ago | — | Jong Kim CEO | — | Series B | 73 patents Engineered Fc-fusion antibody therapeutics and cytokine variant proteins for medical use | — |
| 13 | TRIOAR Developer of drugs for the treatment of cancer 29Moat top 38%Funding top 39%Patents top 41%Innovation top 47% All 7 signals ▾Moattop 38% Fundingtop 39% Patentstop 41% Innovationtop 47% Talentbottom 49% Marketbottom 34% Globalbottom 31% Moat: Editorial + unicorn rating 4/10 · IP moat: 18 patents Funding: Raised $18.0M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $18M | 11 mo ago | 16 | Seongho Woo CEO | — | Series B | 18 patents Targeted antibody-drug conjugates for claudin‑18.2 cancer therapy using novel cleavable linkers | — |
| 14 | Eutilex Developing T cell-based therapeutics and antibodies for the treatment of cancer. | $18M | 114 mo ago | 103 | Byoung Kwon Founder & CEO | PHPGSAPApache HTTP Server+6 | Public | 191 patents Immuno‑oncology therapeutics: checkpoint antibodies, bispecifics, CAR‑T, and immune adjuvants | — |
| 15 | MediMabBio Developer of immunotherapeutics for treating cancer 29Moat top 32%Funding top 35%Talent top 38%Patents top 40% All 8 signals ▾Moattop 32% Fundingtop 35% Talenttop 38% Patentstop 40% Innovationtop 42% Globalbottom 31% Marketbottom 30% Techbottom 26% Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents Funding: Raised $17.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $18M | 7 mo ago | 19 | Hongseok Jo Co-Founder | WordPressMySQLPHP+12 | Series B | 28 patents Immune checkpoint antibodies (TIGIT, GITR) and cytokine‑fusion proteins for cancer immunotherapy | — |
| 16 | Daan Biotherapeutics Developer of therapeutics for cancer treatment 19Moat top 38%Talent top 38%Patents top 43%Funding top 44% All 9 signals ▾Moattop 38% Talenttop 38% Patentstop 43% Fundingtop 44% Innovationbottom 47% Globalbottom 40% Growthbottom 35% Techbottom 31% Marketbottom 19% Moat: Editorial + unicorn rating 4/10 · IP moat: 8 patents Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 19/100 | $17M | 28 mo ago | 4 | J Han Founder | GnuboardMySQLPHP+18 | Series A | 8 patents Targeted immunotherapy: CEACAM5-specific antibodies and engineered T‑cell receptors for cancer. | — |
| 17 | Centenaire Biosciences Developer of antibody therapies to treat cancer and immune diseases | $16M | 51 mo ago | — | Yang Cheol CEO | ZURB FoundationNginxCloudflare+23 | Series A | 14 patents Engineered multi‑Fc antibody fusion proteins for enhanced therapeutic binding and effector functions. | 2 launchs · 1 partnership |
| 18 | CTCELLS Developer of cell-based therapeutics for oncology | $15M | 51 mo ago | — | Minseok Kim CEO | Cart FunctionalitySquarespace CommerceSquarespace+14 | Series B | 43 patents Cell separation and rare cell isolation technologies, plus NK cell differentiation and fusion protein therapeutics. | — |
| 19 | Neogen TC Developer of cell therapies for the treatment of cancer | $13M | 62 mo ago | — | Heejin Lee CEO | — | Series A | — | — |
| 20 | Boostimmune Developer of therapeutics for cancer treatment | $13M | 48 mo ago | 5 | Tadatsugu Taniguchi Co-Founder | — | Series A | 10 patents TCTP-based cancer biomarkers and therapeutic agents for immune‑modulating oncology. | — |
| 21 | SillaJen Developer of oncolytic immunotherapeutics for the treatment of cancer | $12M | 123 mo ago | 49 | — | PHPGoogle MapsYouTube+10 | Public | 113 patents Oncolytic virus therapies and advanced drug delivery formulations for cancer treatment | — |
| 22 | EyeGene Developer of immune vaccines and diagnostic systems for eye disorders | $12M | 102 mo ago | 89 | — | GnuboardMySQLPHP+10 | Public | 164 patents Peptide multiplex diagnostics and mRNA/viral protein vaccine delivery technologies. | — |
| 23 | Connext Provider of therapeutic solution for treating orphan diseases 22Funding top 36%Moat top 38%Patents top 49%Innovation bottom 45% All 8 signals ▾Fundingtop 36% Moattop 38% Patentstop 49% Innovationbottom 45% Talentbottom 45% Globalbottom 31% Marketbottom 29% Techbottom 29% Funding: Raised $9.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 22/100 | $10M | 3 mo ago | 23 | Woo-Jong Lee CEO & Owner | GnuboardMySQLPHP+15 | Series C | 9 patents Stabilized collagenase enzyme formulations for biomedical and industrial applications | — |
| 24 | Txinno Developer of therapeutics for the treatment of cancer | $8M | 58 mo ago | 25 | Chan-Sun Park CEO & Co-Founder | — | Series A | — | — |
| 25 | PharmAbcine Developer of monoclonal antibodies for the treatment of cancer and inflammatory diseases | $6M | 168 mo ago | 48 | — | ImwebFroala EditorYouTube+18 | Public | 149 patents Therapeutic antibodies and fusion proteins targeting VEGFR2 and Tie2 for angiogenesis inhibition | — |
| 26 | Ingenium Therapeutics Developer of anti-cancer immunotherapy treatments | $4M | 31 mo ago | 14 | Sangyong Kim Co-Founder | — | Series A | 5 patents NK cell activation agents for immunotherapy | — |
| 27 | Genome & Company Developer of microbiome-based immuno-oncology drugs | $3M | 73 mo ago | 108 | Jisoo Pae Co-Founder & CEO | — | Public | 252 patents Patents concentrated in computing, sensing & instrumentation | — |
| 28 | CrossPoint Therapeutics Developer of immunotherapies for cancer treatment 27Moat top 45%Patents top 47%Funding bottom 46%Talent bottom 45% All 6 signals ▾Moattop 45% Patentstop 47% Fundingbottom 46% Talentbottom 45% Innovationbottom 40% Globalbottom 31% Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents Patents: 5 patents matched (strict assignee match) · 5 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 27/100 | $2M | 2 mo ago | — | Tae-Erk Kim Co-Founder & CEO | — | Seed | 5 patents Patents concentrated in chemistry & materials | — |
| 29 | Vaxdigm Developer of vaccines and immunotherapies for infectious disease 14Moat top 38%Patents top 45%Innovation top 50%Funding bottom 41% All 6 signals ▾Moattop 38% Patentstop 45% Innovationtop 50% Fundingbottom 41% Globalbottom 31% Marketbottom 26% Moat: Editorial + unicorn rating 4/10 · IP moat: 13 patents Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 14/100 | $2M | 19 mo ago | 9 | — | — | Series A | 13 patents Viral nucleocapsid-based platforms for protein expression and self-assembling nanoparticle vaccines | — |
Top 12 Immunotherapy companies in South Korea
#1
Public · Daejeon, Daejeon · founded 2016 · 38 employees$92Mraised▾
Public · Daejeon, Daejeon · founded 2016 · 38 employees
Developer of cell-penetrating antibodies as oncology therapeutics. It has a proprietary cell-penetrating antibody technology and is developing monoclonal antibodies to directly target the activated form of RAS. The cell-penetrating technology develops antibodies that can access the cytosol of living cells following receptor-mediated endocytosis. RAS proteins function to transmit signals within cells that control cell growth, differentiation, and survival. The product pipeline includes ORM-5029, ORM-6151, and ANDC-0001 for solid tumors and hematological cancers
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 19%Patents
top 23%Moat
top 26%Innovation
top 35%Talent
top 41%Growth
top 47%Funding: Raised $92.0M across 4 rounds · 4 rounds over 9 yrs (0.4/yr) · Last round Post IPO (Dec 2025)
Patents: 121 patents matched (strict assignee match) · 66 filings since 2022 vs 53 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 121 patents · Soonicorn
Audience (LinkedIn): 7k LinkedIn followers — 31.0% of this cohort's audience · 87 engagements/post (1.7× cohort median)
Hiring (LinkedIn): 1 hiring post in 12 mo (public)
Funding rounds
- Dec 2025Post IPO$100M
- Jun 2021Series B$54M
- Jul 2019Series B$30M
- Jun 2017Series A$8M
Founders & team
Investors
IMM Investment, KDB Investment, Atinum Investment, InterVest, KB Investment, Smile Gate Investment
Tech stack
AngularCart FunctionalityCore-JsGodaddyGoogle Font ApiGoogle Workspace
#2
Series C · Seoul, Seoul · founded 2021 · 18 employees$23.5Mraised▾
Series C · Seoul, Seoul · founded 2021 · 18 employees
Developer of immunotherapeutics for cancer treatment. It offers multi-specific antibodies which include MB101, MB201, MB301, and MB401 for the treatment of multiple cancer. It offers multi-antibody platform technology to develop multiple antibodies.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 29%Talent
bottom 49%Market
bottom 36%Global
bottom 29%Funding: Raised $23.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series C (Mar 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Market: 18 employees
Funding rounds
- Mar 2026Series C$23.5M
- Series A—
- Series B—
Founders & team
Investors
Premier Partners, Partners Investment, Korean Development Bank, Wonik Investment Partners, Shinhan Financial Group, Atinum Investment
#3
Series C · Yeongcheon si, North Gyeongsang Province · founded 2017 · 23 employees$9.9Mraised▾
Series C · Yeongcheon si, North Gyeongsang Province · founded 2017 · 23 employees
Provider of therapeutic solution for treating orphan diseases. The company pipeline products are TLR and TLR5 which can be used for agonists in pathogen recognition and activation of innate immunity, pathogen-associated molecular patterns (PAMPs) used for diseases like GvHD, Mucositis, and ARS. Other products offered by the company are Collagenase enzymes derived from microorganisms that break down collagen and used for the treatment of different musculoskeletal diseases like Dupuytren’s contracture, Peyronie’s Disease, Cellulite, and Wound debridement.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Funding
top 36%Moat
top 38%Patents
top 49%Innovation
bottom 45%Talent
bottom 45%Global
bottom 31%Funding: Raised $9.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series C (Mar 2026)
Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents
Patents: 9 patents matched (strict assignee match) · 9 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Funding rounds
- Mar 2026Series C$9.9M
Founders & team
Investors
PharmaResearch, ES Investor, Premier Partners, Murex Partners, Thenextlab, Su Investment Capital
Tech stack
Animate.CssAosApache Http ServerCdnjsCloudflareGnuboard
#4
Series B · Seongnam-si, Gyeonggi-do · founded 2017 · 19 employees$17.8Mraised▾
Series B · Seongnam-si, Gyeonggi-do · founded 2017 · 19 employees
MediMabBio is a developer of immunotherapeutics for treating cancer. The company develops immuno-oncology drugs using its drug discovery platform with a combination of systems biology and immunological solutions to target solid tumors. The products pipeline includes immune checkpoint antibody (MMB-101) in lead optimization stage and immuno cytokine agents (MMB-201) in hit optimization stage.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Moat
top 32%Funding
top 35%Talent
top 38%Patents
top 40%Innovation
top 42%Global
bottom 31%Moat: Editorial + unicorn rating 5/10 · IP moat: 28 patents
Funding: Raised $17.8M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Oct 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 571 LinkedIn followers — 2.5% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series B$17.8M
Founders & team
Investors
KB Investment, Smile Gate Investment, BNH INVESTMENT, Hyundai-invest.com, iM Investment Partners, Time Polio Asset Management
Tech stack
Apache Http ServerBootstrapCookieyesGoogle AnalyticsGoogle Font ApiJquery
#5
Seed · Hwaseong, Gyeonggi do · founded 2022$2.4Mraised▾
Seed · Hwaseong, Gyeonggi do · founded 2022
Developer of immunotherapies for cancer treatment. It offers Stealth-Body technology and Fc inert antibody platform for development of antibody therapies which include CPP-001 for Protein delivery, CPS-001 for Small molecule delivery, and CPR-001 for Gene delivery to cure cancer.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Moat
top 45%Patents
top 47%Funding
bottom 46%Talent
bottom 45%Innovation
bottom 40%Global
bottom 31%Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents
Patents: 5 patents matched (strict assignee match) · 5 filings since 2022 vs 0 in 2017-21 · Latest publication 2025
Funding: Raised $2.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Mar 2026)
Funding rounds
- Mar 2026Seed$2.4M
Founders & team
Investors
Kudos Ventures, Y-Biologics, BMI Korea, SU Investment, Kite Entrepreneurship Foundation, Korea Omega Investment Corp
#6
Series B · Yuseong District, Hoseo · founded 2021 · 16 employees$18Mraised▾
Series B · Yuseong District, Hoseo · founded 2021 · 16 employees
Developer of drugs for the treatment of cancer. The company has developed a proprietary treatment-based Trio technology platform known as Oar1, Oar2, and Oar3 that detects targets, and induces cancer cell death. The technology is applied for various diseases, inflammation, autoimmunity, including cancer.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Moat
top 38%Funding
top 39%Patents
top 41%Innovation
top 47%Talent
bottom 49%Market
bottom 34%Moat: Editorial + unicorn rating 4/10 · IP moat: 18 patents
Funding: Raised $18.0M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) · Last round Series B (Jul 2025)
Patents: 18 patents matched (strict assignee match) · 18 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Funding rounds
- Jul 2025Series B$18M
- Feb 2022Seed—
Founders & team
Investors
KB Investment, IMM Investment, WOORI Venture Partners, Shinhan Venture Investment, Hyundai Venture Investment, Regent Partners
#7
Public · Seoul, Seoul · founded 2014 · 68 employees$2.4Braised▾
Public · Seoul, Seoul · founded 2014 · 68 employees
Cellid is involved in developing personalized vaccines for treating cancer and infectious diseases. They have developed a platform, CeliVax, which activates the anti-cancer immune system which allows the immune cells to detect and kill cancer cells. Their pipeline products include BVAC-C is being investigated for cervical, head, and neck cancer, and BVAC-B for gastric cancer. The candidates are in phase II clinical trial.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Patents
top 32%Funding
top 35%Innovation
top 40%Moat
top 45%Market
bottom 48%Global
bottom 35%Patents: 32 patents matched (strict assignee match) · 26 filings since 2022 vs 4 in 2017-21 · Latest publication 2026
Funding: Raised $2.4B across 1 rounds · 1 rounds over 12 yrs (0.1/yr) · Last round Series A (2016)
Innovation: 32 patents (top 57% of patent-holders) · 26 filings since 2022 vs 4 in 2017-21
Funding rounds
- 2016Series A—
- 2015Series A—
- 2014Series A—
- 2014Series A—
Investors
Amicogen, Korea Health Industry Development Institute, DSC Investment, DAOL Investment, STIC Investments, Green crosscell
Tech stack
JqueryJquery UiKakaoMicrosoft 365Naver AnalyticsNginx
#8
Series A · Seoul, Seoul · founded 2021 · 9 employees$1.9Mraised▾
Series A · Seoul, Seoul · founded 2021 · 9 employees
Developer of vaccines and immunotherapies for infectious disease. It offers synthetic antigen vaccines using microorganisms and animal cells for rapid protein development and production, DNA vaccine, and mRNA vaccine for covid and viral diseases.
Fliar Intelligence Index™ 14how this company ranks against its industry peers
Moat
top 38%Patents
top 45%Innovation
top 50%Funding
bottom 41%Global
bottom 31%Market
bottom 26%Moat: Editorial + unicorn rating 4/10 · IP moat: 13 patents
Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Innovation: 13 patents (top 81% of patent-holders) · 13 filings since 2022 vs 0 in 2017-21
Funding rounds
- Oct 2024Series A$1.9M
Investors
LITALCO, Korea Alternative Investment, The Invention Lab, New Paradigm Investment, Findus, InfoBank
#9
Public · Suwon-si, Gyeonggi-do · founded 2020 · 25 employees$33.8Mraised▾
Public · Suwon-si, Gyeonggi-do · founded 2020 · 25 employees
Developer of antibody therapeutics to treat cancer and autoimmune diseases. The company has developed a platform technology called ePendy that can generate antibody therapeutics for the treatment of autoimmune diseases and cancer.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Moat
top 32%Funding
top 33%Patents
top 36%Innovation
top 45%Market
bottom 41%Global
bottom 40%Moat: Editorial + unicorn rating 4/10 · IP moat: 23 patents
Funding: Raised $33.8M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) · Last round Series B (Jul 2023)
Patents: 23 patents matched (strict assignee match) · 23 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Funding rounds
- Jul 2023Series B$15.5M
- Aug 2021Series A$14.7M
- Jan 2021Seed$3.6M
Investors
KB Investment, Atinum Investment, Partners Investment, CJ Investment, K2 Investment Partners, Shinhan Venture Investment
#10
Series A · Seoul, Seoul · founded 2020 · 4 employees$17.2Mraised▾
Series A · Seoul, Seoul · founded 2020 · 4 employees
Developer of therapeutics for cancer treatment. It offers immune-based cell therapies against lung cancer that expresses T Cell Receptors(TCR) based on natural killer cells and target EGFR mutations.
Fliar Intelligence Index™ 19how this company ranks against its industry peers
Moat
top 38%Talent
top 38%Patents
top 43%Funding
top 44%Innovation
bottom 47%Global
bottom 40%Moat: Editorial + unicorn rating 4/10 · IP moat: 8 patents
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Patents: 8 patents matched (strict assignee match) · 8 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Funding rounds
- Jan 2024Series A$17.2M
Founders & team
Investors
Solasta Ventures, Company K Partners, Paratus Investment, Atinum Investment, Stonebridge Capital, Daily Partners
Tech stack
Animate.CssAosApache Http ServerBootstrapCdnjsCloudflare
#11
Series B · Seoul, Seoul · founded 2000$22.8Mraised▾
Series B · Seoul, Seoul · founded 2000
Developer of immunotherapies for immune diseases and cancer. It offers a pipeline of drug candidates which include PG-102 for obesity, PG-208, PG-202, and others for oncology. It is based on NTIG (Neo Tri-ImmunoGlobulin) and Cyt-NTIG technology that overcomes the systemic side effects of cytokines through specific targeting.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Growth
top 5%Partners
top 18%News
top 19%Moat
top 25%Patents
top 39%Innovation
top 48%Partners: 5 contract events in 12 mo · Named contractor/client in 5 deals
News: 9 BI events in 12 mo (of 12 tracked, 4 types) · +350% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding rounds
- Apr 2023Series B$22.8M
Founders & team
Investors
Yuhan Corporation
#12
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 21 employees$60.5Mraised▾
Public · Seongnam-si, Gyeonggi-do · founded 2016 · 21 employees
Developer of monoclonal and specific antibody for cancer treatment. The company's lead antibody IMC-001 is currently in phase 1 of the clinical trial. The company has a pipeline of immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.
Fliar Intelligence Index™ 11how this company ranks against its industry peers
Funding
top 37%Moat
top 39%Market
bottom 32%Global
bottom 32%Tech
bottom 23%Funding: Raised $60.5M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) · Last round Series B (Jan 2022)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Market: 21 employees · Top-50,000,000 web property
Audience (LinkedIn): 563 LinkedIn followers — 2.5% of this cohort's audience
Funding rounds
- Jan 2022Series B$20.5M
- Feb 2019Series A$40M
Investors
Yuhan Corporation, Premier Partners, K2 Investment Partners, BNH INVESTMENT, E&Investment, Hanyang Securities
Tech stack
Apache Http ServerCore-JsFont AwesomeGoogle Font ApiGsapIis
Funding & investor landscape
$3.3Btotal disclosed funding
29companies funded
40disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Sj Lee
CEO · Orum Therapeutics
Kim Seop
CEO · Must Bio
Woo-Jong Lee
CEO & Owner · Connext
Hongseok Jo
Co-Founder · MediMabBio
Jennifer Kang
Co-Founder & Co-CEO · MediMabBio
Tae-Erk Kim
Co-Founder & CEO · CrossPoint Therapeutics
Seongho Woo
CEO · TRIOAR
J Han
Founder · Daan Biotherapeutics
Byoung Cho
CEO · Daan Biotherapeutics
Jong Kim
CEO · Progen
Young Sung
Founder & Chairman · Genexine
Neil Warma
CEO · Genexine
Prism market signals · South Korea · country-scoped Prism corpus, 602,944 docs
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · South Korea
How research on Immunology & Immunotherapy is moving in South Korea
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,328 South Korea-affiliated papers.
research sentiment over time
201720212026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and softening — the enthusiastic (strongly-positive) share moved 82% → 68% across 2017–2026.
top research entities
- Ministry of Education188
- National Cancer Center137
- Asan Medical Center123
- Seoul National University96
- Samsung Medical Center86
leading researchers
Sun Young Rha · Hong Jae Chon · Sehhoon Park · Jae‐Lyun Lee · Min‐Hee Ryu · S. Lee · Se Hoon Park · Seok Jin Kim
▲
Breakthroughs363 · 27%
▲ 0%→28% share
0 median citations97% since 2021mostly methods-led
Breakthroughs are rising (0%→28% of field), led by Immune system.
rising sub-themes (early→recent)
- Immune system1→178
- Immune checkpoint2→31
- Lung cancer1→18
- Oncology1→12
- Pembrolizumab1→5
Newly emergingCancer immunotherapy 0→86 · Tumor microenvironment 0→85 · Cancer research 0→64
Landmark Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level · 1,117 cites
◆
Advancements679 · 51%
▼ 67%→50% share
▼0.7× share momentum0 median citations92% since 2021mostly empirical
Advancements are cooling (67%→50% of field), led by Immune system.
rising sub-themes (early→recent)
- Immune system5→255
- Cancer2→112
- Tumor microenvironment1→92
- Internal medicine3→77
- Cancer research2→71
Newly emergingImmune checkpoint 0→40 · Hepatocellular carcinoma 0→36 · Biomarker 0→33
Landmark Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma · 3,353 cites
▼
Concerns179 · 13%
▲ 8%→14% share
▲1.8× share momentum0 median citations95% since 2021mostly reviews
Concerns are rising (8%→14% of field), led by Immune system.
rising sub-themes (early→recent)
- Immune system60
- Cancer39
- Cancer research26
- Oncology25
- Tumor microenvironment21
Newly emergingImmune system 0→56 · Cancer 0→35 · Oncology 0→23
Landmark Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer · 2,789 cites
RESEARCH HOTSPOTS · South Korea
Where immunology is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Seoul557 · +0.49
Daejeon95 · +0.59
Seongnam-si88 · +0.43
Ulsan57 · +0.45
Gwangju50 · +0.52
Busan39 · +0.49
Daegu38 · +0.51
Suwon38 · +0.57
Incheon34 · +0.36
Jeonju18 · +0.54
PATENT SIGNAL · South Korea
Who's filing immunology patents in South Korea
South Korea immunology patent filing is accelerating — 699 filings from 413 assignees (2016–2025), led by Hanall Biopharma, Korea Advanced INST SCI & TECH, UNIV Yonsei IACF; annual filings 32→100.
699 filings413 assigneespeak 110/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Hanall Biopharma47
- Korea Advanced INST SCI & TECH37
- UNIV Yonsei IACF36
- Seoul NAT UNIV R&DB Foundation26
- UNIV Korea RES & BUS Found25
- Catholic UNIV Korea IND Academic23
- Parenchyma Biotech20
- Innovo Therapeutics20
Common questions
How many Immunotherapy companies are there in South Korea?
Radar tracks 81 indexable Immunotherapy companies headquartered in South Korea that meet our profile-completeness bar.
What is the total funding raised by Immunotherapy companies in South Korea?
The Immunotherapy companies in South Korea on this list have raised a combined $3.3B in disclosed equity funding across 29 funded companies.
Which is the highest-funded Immunotherapy company in South Korea?
Cellid is the highest-funded Immunotherapy company in South Korea, with $2.4B in disclosed equity funding.
How many Immunotherapy companies in South Korea are funded?
29 of the 81 Immunotherapy companies in South Korea on this list have disclosed at least one equity funding round.
How many Immunotherapy unicorns are there in South Korea?
None of the Immunotherapy companies in South Korea on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in South Korea Immunotherapy companies?
The most active investors in South Korea Immunotherapy companies on this list include DSC Investment, Wooshin Venture Investment, IMM Investment, Korea Investment Holdings, Company K Partners.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.